bucindolol has been researched along with Coronary Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muller, CA; Opie, LH; Peisach, M; Pineda, CA | 1 |
| Berdeaux, A; Bonhenry, C; Giudicelli, JF | 1 |
2 other study(ies) available for bucindolol and Coronary Disease
| Article | Year |
|---|---|
Bucindolol, a beta blocker, decreased ventricular fibrillation and maintained mechanical function in a pig model of acute myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Disease Models, Animal; Female; Heart Rate; Hemodynamics; Male; Propanolamines; Swine; Ventricular Fibrillation; Ventricular Function, Left | 1992 |
Vasodilating beta-adrenoceptor blocking drugs do not redistribute myocardial flow during acute coronary ligation in dogs.
Topics: Adrenergic beta-Antagonists; Animals; Coronary Circulation; Coronary Disease; Dogs; Electrocardiography; Female; Hemodynamics; Labetalol; Male; Myocardial Contraction; Propanolamines; Vascular Resistance; Vasodilator Agents | 1985 |